KR20210139271A - Crispr/cas 융합 단백질 및 시스템 - Google Patents
Crispr/cas 융합 단백질 및 시스템 Download PDFInfo
- Publication number
- KR20210139271A KR20210139271A KR1020217029732A KR20217029732A KR20210139271A KR 20210139271 A KR20210139271 A KR 20210139271A KR 1020217029732 A KR1020217029732 A KR 1020217029732A KR 20217029732 A KR20217029732 A KR 20217029732A KR 20210139271 A KR20210139271 A KR 20210139271A
- Authority
- KR
- South Korea
- Prior art keywords
- lys
- leu
- glu
- gly
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806708P | 2019-02-15 | 2019-02-15 | |
| US62/806,708 | 2019-02-15 | ||
| PCT/US2020/018145 WO2020168102A1 (en) | 2019-02-15 | 2020-02-13 | Crispr/cas fusion proteins and systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210139271A true KR20210139271A (ko) | 2021-11-22 |
Family
ID=70166116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217029732A Ceased KR20210139271A (ko) | 2019-02-15 | 2020-02-13 | Crispr/cas 융합 단백질 및 시스템 |
Country Status (11)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| SG11202108812SA (en) | 2019-02-15 | 2021-09-29 | Sigma Aldrich Co Llc | Crispr/cas fusion proteins and systems |
| KR20260037664A (ko) * | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| CN116063546B (zh) * | 2021-10-29 | 2026-01-16 | 中科辅酶医科技(深圳)有限公司 | 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用 |
| US20230265405A1 (en) * | 2022-02-22 | 2023-08-24 | Massachusetts Institute Of Technology | Engineered nucleases and methods of use thereof |
| AU2023232138A1 (en) * | 2022-03-08 | 2024-09-26 | Wake Forest University Health Sciences | Compositions, systems and methods for eukaryotic gene editing |
| WO2025221793A1 (en) * | 2024-04-16 | 2025-10-23 | Monsanto Technology Llc | Modified cas proteins for nuclear localization and editing activity in plants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232430A1 (en) | 2001-11-26 | 2003-12-18 | Advanced Cell Technology | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| DK3363902T3 (da) * | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| WO2014186686A2 (en) * | 2013-05-17 | 2014-11-20 | Two Blades Foundation | Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases |
| AU2014310360B2 (en) * | 2013-06-11 | 2019-10-24 | PPL (BVI) Limited | Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides |
| JP6793547B2 (ja) * | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物 |
| AU2015219339B2 (en) * | 2014-02-19 | 2020-03-05 | Bioasis Technologies Inc. | P97-IDS fusion proteins |
| EP3981876A1 (en) | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| EP3845655B1 (en) | 2014-10-01 | 2025-01-01 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| EP3313445A1 (en) | 2015-06-24 | 2018-05-02 | Sigma Aldrich Co. LLC | Cell cycle dependent genome regulation and modification |
| JP6867689B2 (ja) * | 2016-01-29 | 2021-05-12 | 国立大学法人東京工業大学 | Cas9−gRNA複合体の細胞核内への導入方法、及び細胞内における標的遺伝子の改変方法 |
| WO2017173004A1 (en) * | 2016-03-30 | 2017-10-05 | Mikuni Takayasu | A method for in vivo precise genome editing |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| CN107579793A (zh) * | 2016-07-04 | 2018-01-12 | 中兴通讯股份有限公司 | 一种通信网络设备间时间同步的优化方法、装置及设备 |
| WO2018027078A1 (en) * | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| KR20240007715A (ko) * | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US11242513B2 (en) | 2016-12-14 | 2022-02-08 | Wageningen Universiteit | Thermostable Cas9 nucleases |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| CA3071769A1 (en) | 2017-07-31 | 2019-02-07 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
| US11071791B2 (en) * | 2018-01-26 | 2021-07-27 | Wisconsin Alumni Research Foundation | Vector for gene silencing and replacement and methods of use thereof |
| WO2019161290A1 (en) | 2018-02-15 | 2019-08-22 | Sigma-Aldrich Co. Llc | Engineered cas9 systems for eukaryotic genome modification |
| PL3765615T3 (pl) * | 2018-03-14 | 2023-11-13 | Arbor Biotechnologies, Inc. | Nowe enzymy i układy crispr ukierunkowane na dna |
| SG11202108812SA (en) | 2019-02-15 | 2021-09-29 | Sigma Aldrich Co Llc | Crispr/cas fusion proteins and systems |
-
2020
- 2020-02-13 SG SG11202108812SA patent/SG11202108812SA/en unknown
- 2020-02-13 WO PCT/US2020/018145 patent/WO2020168102A1/en not_active Ceased
- 2020-02-13 CN CN202080029346.8A patent/CN113728099A/zh active Pending
- 2020-02-13 JP JP2021547390A patent/JP2022520104A/ja active Pending
- 2020-02-13 CA CA3129835A patent/CA3129835A1/en active Pending
- 2020-02-13 BR BR112021016019-1A patent/BR112021016019A2/pt not_active IP Right Cessation
- 2020-02-13 KR KR1020217029732A patent/KR20210139271A/ko not_active Ceased
- 2020-02-13 AU AU2020221274A patent/AU2020221274B2/en not_active Ceased
- 2020-02-13 EP EP20716979.8A patent/EP3924475A1/en not_active Withdrawn
- 2020-02-13 US US16/790,399 patent/US10947517B2/en active Active
-
2021
- 2021-02-10 US US17/172,734 patent/US11965184B2/en active Active
- 2021-08-02 IL IL285300A patent/IL285300A/en unknown
-
2023
- 2023-04-27 US US18/308,336 patent/US20230287377A1/en not_active Abandoned
- 2023-07-27 JP JP2023122299A patent/JP2023156365A/ja active Pending
-
2024
- 2024-04-09 AU AU2024202275A patent/AU2024202275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024202275A1 (en) | 2024-05-23 |
| SG11202108812SA (en) | 2021-09-29 |
| US10947517B2 (en) | 2021-03-16 |
| JP2022520104A (ja) | 2022-03-28 |
| AU2020221274B2 (en) | 2024-02-08 |
| JP2023156365A (ja) | 2023-10-24 |
| US11965184B2 (en) | 2024-04-23 |
| EP3924475A1 (en) | 2021-12-22 |
| US20200263155A1 (en) | 2020-08-20 |
| US20230287377A1 (en) | 2023-09-14 |
| CN113728099A (zh) | 2021-11-30 |
| WO2020168102A1 (en) | 2020-08-20 |
| BR112021016019A2 (pt) | 2021-10-05 |
| US20210163910A1 (en) | 2021-06-03 |
| AU2020221274A1 (en) | 2021-08-26 |
| IL285300A (en) | 2021-09-30 |
| CA3129835A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102655021B1 (ko) | 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용 | |
| KR102458395B1 (ko) | 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선 | |
| KR102494449B1 (ko) | 진핵 게놈 변형을 위한 조작된 cas9 시스템 | |
| US20230287377A1 (en) | Crispr/cas fusion proteins and systems | |
| CN111263812A (zh) | 用于crispr/cas激活系统的合成的指导rna | |
| KR20260032649A (ko) | 타우 시딩 또는 응집의 유전적 변형제를 식별하기 위한 CRISPR/Cas 스크리닝 플랫폼 | |
| AU2021236230B2 (en) | High fidelity SpCas9 nucleases for genome modification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |